Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLARIS: pembrolizumab + lenvatinib after prior IO-based therapy in advanced hepatocellular carcinoma
2024-515731-29-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Started Oct 2024; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-515731-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515731-29-00.